Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Lease Agreements (Tables)

9 Months Ended

Sep. 30, 2021

The components of our operating lease expense were as follows (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
Fixed operating lease expense	$	1,340	$	1,340	$	4,020	$	4,020
Variable operating lease expense		259		237		651		704
Total operating lease expense	$	1,599	$	1,577	$	4,671	$	4,724

Supplemental information related to our operating lease were as follow (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
Cash payments included in the measurement of operating lease liabilities	$	2,529	$	2,431	$	7,554	$	7,263


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
Fixed operating lease expense	$	1,340	$	1,340	$	4,020	$	4,020
Variable operating lease expense		259		237		651		704
Total operating lease expense	$	1,599	$	1,577	$	4,671	$	4,724

Supplemental information related to our operating sublease was as follow (in thousands):

The following table presents the future lease payments of our operating lease liabilities as of September 30, 2021 (in thousands):


		Operating Lease		Sublease Receipts		Net
Remainder of 2021	$	2,529	$	(1,137)	$	1,392
2022		10,485		(4,716)		5,769
2023		877		(394)		483
Total minimum payments required	$	13,891	$	(6,247)	$	7,644